Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Does bone marrow biopsy done at the end of induction factor into your decision?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Does treating CLL reduce the risk of non-melanoma skin cancers?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL.
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?